Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has received a consensus broker rating score of 1.13 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.
Brokerages have set a 1-year consensus target price of $27.00 for the company and are forecasting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Clementia Pharmaceuticals an industry rank of 184 out of 265 based on the ratings given to its competitors.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. Wedbush reissued an “outperform” rating and issued a $26.00 target price on shares of Clementia Pharmaceuticals in a research note on Tuesday, November 14th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. J. Goldman & Co LP bought a new stake in shares of Clementia Pharmaceuticals in the 4th quarter valued at about $488,000. Driehaus Capital Management LLC lifted its stake in shares of Clementia Pharmaceuticals by 5.2% in the 4th quarter. Driehaus Capital Management LLC now owns 862,279 shares of the company’s stock valued at $16,366,000 after acquiring an additional 42,771 shares during the last quarter. Sectoral Asset Management Inc lifted its stake in shares of Clementia Pharmaceuticals by 148.5% in the 4th quarter. Sectoral Asset Management Inc now owns 75,313 shares of the company’s stock valued at $1,429,000 after acquiring an additional 45,000 shares during the last quarter. Alps Advisors Inc. bought a new stake in shares of Clementia Pharmaceuticals in the 4th quarter valued at about $642,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Clementia Pharmaceuticals by 12.7% in the 4th quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock valued at $659,000 after acquiring an additional 3,920 shares during the last quarter. 68.40% of the stock is owned by institutional investors.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.